Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals Ownership Summary
Zentalis Pharmaceuticals is owned by 67.69% institutional investors, 21.76% insiders, and 10.56% retail investors. Blackrock is the largest institutional shareholder, holding 6.80% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.
ZNTL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Zentalis Pharmaceuticals | 67.69% | 21.76% | 10.56% |
| Sector | Healthcare Stocks | 244.59% | 12.11% | -156.70% |
| Industry | Biotech Stocks | 379.61% | 11.70% | -291.31% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock | 4.82M | 6.80% | $19.71M |
| 5am venture management | 3.95M | 5.51% | $9.24M |
| Two sigma investments, lp | 2.96M | 4.13% | $6.92M |
| Acadian asset management | 2.85M | 3.97% | $6.66M |
| Vanguard group | 2.86M | 3.96% | $3.86M |
| Renaissance | 1.94M | 2.70% | $4.54M |
| Citadel advisors | 1.73M | 2.42% | $4.05M |
| Tang capital management | 1.55M | 2.15% | $2.34M |
| D. e. shaw | 1.48M | 2.07% | $3.47M |
| Two sigma advisers, lp | 1.46M | 2.03% | $2.21M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Mayo clinic | 187.14K | 25.27% | $765.41K |
| Tybourne capital management (hk) | 961.49K | 4.69% | $1.45M |
| 5am venture management | 3.95M | 2.56% | $9.24M |
| Pfizer | 953.83K | 0.84% | $2.00M |
| Peapod lane capital | 366.87K | 0.68% | $834.58K |
| Decheng capital | 1.32M | 0.47% | $3.10M |
| Opaleye management | 1.41M | 0.44% | $3.31M |
| Stonepine capital management | 269.10K | 0.25% | $629.69K |
| Anfield capital management | 274.52K | 0.18% | $642.37K |
| Boxer capital | 450.00K | 0.10% | $1.84M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Two sigma investments, lp | 2.96M | 0.01% | 1.49M |
| Balyasny asset management | 970.86K | 0.00% | 970.86K |
| Qube research | 637.12K | 0.00% | 619.64K |
| Millennium management | 1.29M | 0.00% | 616.69K |
| Susquehanna group, llp | 571.26K | 0.00% | 560.91K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Matrix capital management company, lp | - | - | -13.96M |
| Eventide asset management | - | - | -4.48M |
| T. rowe price investment management | - | - | -1.33M |
| Bioimpact capital | - | - | -1.11M |
| Integral health asset management | - | - | -1.05M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard fiduciary trust | 304.47K | 0.00% | 304.47K | $712.46K |
| Simplex trading | 98.55K | 0.00% | 98.55K | $230.62M |
| Norges bank | 71.53K | - | 71.53K | $292.55K |
| Private advisor group | 31.47K | 0.00% | 31.47K | $73.64K |
| State of wyoming | 28.47K | 0.01% | 28.47K | $66.61K |
Sold Out
| Holder | Change |
|---|---|
| Caitong asset management | -1.00 |
| Gamma investing | -2.00 |
| True wealth design | -9.00 |
| Farther finance advisors | -10.00 |
| Advisor group | -10.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 122 | 17.31% | 47,559,177 | 17.93% | 67 | 2.05% | 65 | 14.04% | 32 | 18.52% |
| Mar 31, 2026 | 34 | -60.00% | 9,201,108 | -77.33% | 12 | 0.41% | 18 | -51.35% | 7 | -75.00% |
| Dec 31, 2025 | 51 | -49.00% | 21,959,982 | -58.38% | 30 | 0.57% | 19 | -53.66% | 20 | -39.39% |
| Sep 30, 2025 | 95 | -13.64% | 52,043,002 | 0.86% | 72 | 1.41% | 41 | -24.07% | 28 | -31.71% |
| Jun 30, 2025 | 115 | -12.21% | 55,620,773 | 31.52% | 77 | 2.22% | 58 | -1.69% | 42 | -14.29% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 2.83M | 3.96% | -2.12M |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.19M | 3.17% | - |
| Vanguard Morn Total Stk Mkt Idx Investor | 2.19M | 3.07% | - |
| Vanguard Total Stock Mkt Idx Inv | 2.19M | 3.07% | - |
| Vanguard US Total Market Shares ETF | 1.89M | 2.64% | - |
| Eventide Gilead N | 1.64M | 2.30% | -1.94M |
| iShares Russell 2000 ETF | 1.21M | 1.69% | -21.50K |
| Fidelity Growth Compy Commingled Pl O | 1.16M | 1.63% | - |
| FIAM Small Cap Core CIT Cl B | 886.80K | 1.25% | 11.50K |
| Fidelity Growth Compy Commingled Pl S | 881.46K | 1.24% | -280.77K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Aug 14, 2026 | WALTERS GROUP | - | Buy | $15.17M |
| Feb 09, 2026 | Bruns Ingmar | Chief Medical Officer | Sell | $801.62 |
| Feb 06, 2026 | Bruns Ingmar | Chief Medical Officer | Sell | $7.20K |
| Feb 09, 2026 | Vultaggio Vincent | PAO and PFO | Sell | $8.09K |
| Feb 06, 2026 | Vultaggio Vincent | PAO and PFO | Sell | $72.77K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | - |
| 2026 Q1 | - | 9 |
| 2025 Q4 | 1 | 1 |
| 2025 Q3 | - | - |
| 2025 Q2 | 1 | - |
ZNTL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools